Daily Cardiology Research Analysis
Analyzed 75 papers and selected 3 impactful papers.
Summary
Analyzed 75 papers and selected 3 impactful articles.
Selected Articles
1. Lipoprotein(a) and oxidized phospholipids are associated with myocardial inflammation after acute myocardial infarction.
In a randomized, double-blind in-hospital trial context, plasma OxPL species carried on Lp(a) were measured acutely and at 30 days after MI and related to myocardial inflammation on paired imaging. PCSK9 inhibition reduced myocardial inflammation, and the analyses link Lp(a)-bound oxidized phospholipids to the inflammatory response after MI.
Impact: This study provides human, trial-embedded evidence linking Lp(a)-bound oxidized phospholipids to post-MI myocardial inflammation and demonstrates modifiability with PCSK9 inhibition. It advances understanding of inflammatory drivers after MI and nominates Lp(a)/OxPL pathways as therapeutic targets.
Clinical Implications: Supports early lipoprotein(a)/oxidized phospholipid assessment in MI and provides mechanistic rationale for PCSK9 inhibition and future Lp(a)-lowering strategies to mitigate post-MI inflammation and potentially improve remodeling.
Key Findings
- Lp(a)-bound oxidized phospholipids (OxPL-apo(a), OxPL-apoB) were profiled at admission and 30 days post-MI and associated with myocardial inflammatory signals on paired imaging.
- In-hospital PCSK9 inhibition reduced myocardial inflammation compared with placebo.
- The data mechanistically connect Lp(a)/OxPL biology to early post-MI inflammation, suggesting a modifiable pathway.
Methodological Strengths
- Embedded within a randomized, double-blind clinical trial with placebo control
- Paired longitudinal biomarker assessment (admission and 30 days) with imaging correlation
Limitations
- Biomarker analysis appears post hoc with sample size not specified in the abstract
- Detailed imaging modalities, quantitative effect sizes, and external validation are not provided in the abstract
Future Directions: Prospective trials testing Lp(a)-lowering and OxPL-targeting therapies with inflammation and remodeling endpoints after MI; standardized imaging-biomarker platforms to stratify inflammatory risk.
Localized myocardial inflammation after acute myocardial infarction (MI) is regulated by innate immune pathways. Oxidized phospholipids (OxPLs) carried on lipoprotein(a) (Lp(a)) are proinflammatory, but their association with myocardial inflammation during the early post-MI period has not been described. Here we study patients enrolled in a randomized, double-blind trial of in-hospital PCSK9 inhibition versus placebo, in whom this treatment decreased myocardial inflammation after MI. We analyze plasma levels of OxPLs on apolipoprotein B-100 containing lipoproteins (OxPL-apoB), OxPLs on apolipoprotein(a) (OxPL-apo(a)), and Lp(a) during hospital admission and at 30 days, and paired [
2. Impaired Lung BCAA Metabolism Promotes Ferroptosis and Resultant Pulmonary Arterial Hypertension-Associated Hepatopathy.
Multi-omics human data and mechanistic experiments reveal that defective BCAA catabolism promotes ferroptosis in PASMCs, driving PAH and contributing to hepatopathy. Pharmacologic activation of BCAA breakdown with BT2 reverses pulmonary ferroptotic signatures, improves right ventricular function and exercise capacity, and ameliorates hepatic stress phenotypes.
Impact: Identifies BCAA metabolism as a tractable driver of PAH via ferroptosis and connects pulmonary vascular disease to hepatic dysfunction, proposing BT2 as a translational therapeutic strategy.
Clinical Implications: Suggests metabolic modulation (activating BCAA catabolism) to reduce PAH severity and right heart strain, and highlights cross-organ (lung–liver) consequences that may guide holistic management.
Key Findings
- Human PAH PASMCs exhibit altered BCAA homeostasis and deficiencies in BCAA catabolic and ferroptosis pathways.
- Excess BCAAs induce a pro-ferroptotic phenotype in human PASMCs in vitro.
- BT2 activation of BCAA catabolism in monocrotaline-PAH reduces disease severity, improves RV function and exercise capacity, and reverses lung ferroptotic signatures and complement deposition.
- BT2 mitigates hepatic shear-stress phenotypes; human PAH livers recapitulate nuclear expansion and metabolic alterations.
Methodological Strengths
- Integrated human metabolomic and transcriptomic profiling with in vitro mechanistic validation
- In vivo therapeutic testing (BT2) with multi-organ phenotyping and functional endpoints
Limitations
- Predominantly preclinical with uncertain generalizability to diverse human PAH etiologies
- Sample sizes and detailed randomization/blinding procedures are not specified in the abstract
Future Directions: Early-phase clinical trials testing BT2 or alternative strategies to enhance BCAA catabolism in PAH with ferroptosis and right heart endpoints; exploration of lung–liver axis biomarkers for patient selection.
Dysregulated branched-chain amino acid (BCAA) metabolism occurs in pulmonary arterial hypertension (PAH), but its role in pulmonary vascular disease and resultant hepatopathy remains undefined. Here, human metabolomic and transcriptomic analyses identified altered BCAA homeostasis and deficits in BCAA catabolic and ferroptosis pathways in PAH pulmonary artery smooth muscle cells (PASMCs). In vitro, excess BCAAs promoted a pro-ferroptotic phenotype in human PASMCs. In monocrotaline-induced PAH, pharmacologic activation of BCAA catabolism with BT2 reduced disease severity, improved right ventricular function, and enhanced exercise capacity while reversing lung ferroptotic signatures and perivascular complement deposition. BT2 also mitigated hepatic shear stress phenotypes, including hepatocyte nuclear expansion and mitochondrial protein dysregulation. Human PAH livers recapitulated many of the hepatic shear stress phenotypes including nuclear expansion and metabolic alterations. These data implicate impaired BCAA metabolism as a driver of PAH via PASMC ferroptosis and potentially link PAH to hepatic metabolic dysfunction through mechanical stress-associated pathways.
3. S-Nitrosylation of TRAP1 drives the progression of HFpEF through activation of the Rb-E2F axis in cardiomyocytes.
In a two-hit murine HFpEF model, cardiomyocyte-enriched S-nitrosylation of TRAP1 (at Cys501) correlated with diastolic dysfunction and hypertrophy. iNOS inhibition and cardiomyocyte expression of a non-nitrosylatable TRAP1 mutant alleviated HFpEF-like phenotypes, mechanistically via enhanced TRAP1–Rb binding that disrupts Rb–E2F complexes and increases E2F transcriptional activity.
Impact: Reveals a previously unrecognized nitrosative signaling axis (iNOS–SNO-TRAP1–Rb–E2F) that directly reprograms cardiomyocyte growth control in HFpEF, offering precise, mechanism-based targets beyond hemodynamic management.
Clinical Implications: Positions nitrosative stress modulation and prevention of TRAP1 Cys501 S-nitrosylation as candidate strategies to reduce hypertrophy and improve diastolic function in HFpEF.
Key Findings
- TRAP1 S-nitrosylation is markedly increased in HFpEF hearts, enriched in cardiomyocytes, and correlates with diastolic dysfunction and hypertrophy.
- Short-term iNOS inhibition and cardiomyocyte-specific expression of a TRAP1 Cys501A mutant reduce SNO-TRAP1 and alleviate HFpEF-like phenotypes.
- SNO-TRAP1 enhances TRAP1–Rb association, disrupts Rb–E2F binding, and increases E2F transcriptional activity independently of Rb phosphorylation.
Methodological Strengths
- Comprehensive multi-level mechanistic dissection (biotin-switch, co-IP, domain mapping, reporter assays, protein docking)
- Causal testing with pharmacologic iNOS inhibition and cardiomyocyte-targeted TRAP1 mutant in an established HFpEF model
Limitations
- Preclinical mouse-focused study; human validation of SNO-TRAP1 axis and pharmacologic translatability remain untested
- Duration of benefit and safety of long-term nitrosative modulation were not addressed in the abstract
Future Directions: Validate SNO-TRAP1–Rb–E2F signaling in human HFpEF myocardium; develop selective TRAP1 nitrosylation blockers or iNOS-targeted strategies with translational safety profiling.
RATIONALE: Heart failure with preserved ejection fraction (HFpEF) arises from comorbidity-driven meta-inflammation and nitrosative stress, yet how these insults reprogram cardiomyocyte growth control remains unclear. We hypothesized that inducible nitric oxide synthase (iNOS)-dependent S-nitrosylation (SNO) of tumor necrosis factor receptor-associated protein 1 (TRAP1) activates E2F-driven hypertrophic programs by remodeling the retinoblastoma protein (Rb)-E2F signaling axis. METHODS: Biotin-switch assays were used to quantify TRAP1-specific S-nitrosylation (SNO-TRAP1) in hearts from mice subjected to a two-hit HFpEF model (high-fat diet + Nω-nitro-L-arginine methyl ester (L-NAME), 12 weeks) and chow controls, as well as in cardiomyocytes, endothelial cells, and fibroblasts isolated by Langendorff perfusion. Causality was tested using pharmacological iNOS inhibition and cardiomyocyte-targeted expression of TRAP1 wild type or a S-nitrosylation cysteine 501 (Cys501) mutant. TRAP1-Rb-E2F interactions were examined using co-immunoprecipitation, domain mapping, transcriptional reporter assays, and complementary protein-protein docking analyses. RESULTS: TRAP1 S-nitrosylation was markedly increased in HFpEF hearts, with enrichment in cardiomyocytes, and correlated with diastolic dysfunction and cardiac hypertrophy. Short-term iNOS inhibition improved diastolic indices and attenuated hypertrophic remodeling. Cardiomyocyte-specific expression of the TRAP1 Cys501A mutant reduced SNO-TRAP1 and alleviated HFpEF-like phenotypes. Mechanistically, Rb was identified as a novel TRAP1-interacting partner. SNO-TRAP1 enhanced TRAP1-Rb association while disrupting Rb-E2F binding, leading to increased E2F transcriptional activity independently of Rb phosphorylation. CONCLUSIONS: An iNOS-SNO-TRAP1-Rb-E2F axis drives cardiomyocyte hypertrophy and diastolic dysfunction in HFpEF via phosphorylation-independent displacement of E2F from Rb. Targeting nitrosative stress or preventing TRAP1 Cys501 S-nitrosylation engagement may offer mechanism-based therapies for HFpEF.